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Abstract
Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by
unwanted choreatic movements, behavioral and psychiatric disturbances and dementia. Prevalence in the
Caucasian population is estimated at 1/10,000-1/20,000. Mean age at onset of symptoms is 30-50 years. In some
cases symptoms start before the age of 20 years with behavior disturbances and learning difficulties at school
(Juvenile Huntington’s disease; JHD). The classic sign is chorea that gradually spreads to all muscles. All
psychomotor processes become severely retarded. Patients experience psychiatric symptoms and cognitive decline.
HD is an autosomal dominant inherited disease caused by an elongated CAG repeat (36 repeats or more) on the
short arm of chromosome 4p16.3 in the Huntingtine gene. The longer the CAG repeat, the earlier the onset of
disease. In cases of JHD the repeat often exceeds 55. Diagnosis is based on clinical symptoms and signs in an
individual with a parent with proven HD, and is confirmed by DNA determination. Pre-manifest diagnosis should
only be performed by multidisciplinary teams in healthy at-risk adult individuals who want to know whether they
carry the mutation or not. Differential diagnoses include other causes of chorea including general internal disorders
or iatrogenic disorders. Phenocopies (clinically diagnosed cases of HD without the genetic mutation) are observed.
Prenatal diagnosis is possible by chorionic villus sampling or amniocentesis. Preimplantation diagnosis with in vitro
fertilization is offered in several countries. There is no cure. Management should be multidisciplinary and is based
on treating symptoms with a view to improving quality of life. Chorea is treated with dopamine receptor blocking
or depleting agents. Medication and non-medical care for depression and aggressive behavior may be required.
The progression of the disease leads to a complete dependency in daily life, which results in patients requiring full-
time care, and finally death. The most common cause of death is pneumonia, followed by suicide.
Introduction
The first description by Waters, of a patient with what
we now call Huntington’s chorea, dates from 1842. But
it was not until 1872, after the lecture and description
of the disease by George Huntington, that it became
known as Huntington’s chorea. It is a neurodegenerative
disorder passing within families from generation to gen-
eration with onset in middle age and characterized by
unwanted choreatic movements, behavioral and psychia-
tric disturbances and dementia [1] For many decades its
name remained unchanged, until the nineteen-eighties
when, fully aware of the extensive non-motor symptoms
and signs, the name was changed to Huntington’sd i s -
ease (HD). In 1983, a linkage on chromosome 4 was
established and in 1993 the gene for HD was found [2].
That period marked a tremendous increase in interest
in HD and neurogenetic disorders. For the first time,
actual premanifest diagnoses could be made and as
more diseases involving trinucleotide repeats of CAG
were found, HD served as a model for many studies in
medicine. CAG (cytosine (C), adenine (A), and guanine
(G)), is a trinucleotide, the building stone of DNA. CAG
is the codon for the amino acid glutamic. Finding the
gene opened new research lines, new models and for
the first time a real rationale on the way to treat this
devastating disease. Many symptomatic treatments are
now available, but there is a need for better, modifying
drugs.
Epidemiology
Huntington’s disease is a rare neuropsychiatric disorder
with a prevalence of 5-10 per 100,000 in the Caucasian
population. In Japan, a much lower prevalence of about
one-tenth of prevalence of the Caucasion population is
described [3]. Recently, several phenocopies have been
described, all of which have an even lower prevalence
(see paragraph on differential diagnosis).
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The nuclear symptoms and signs of Huntington’s disease
(HD) consist of motor, cognitive and psychiatric distur-
bances. Other less well-known, but prevalent and often
debilitating features of HD include unintended weight
loss, sleep- and circadian rhythm disturbances and auto-
nomic nervous system dysfunction. The mean age at
onset is between 30 and 50 years, with a range of 2 to 85
years. The mean duration of the disease is 17-20 years.
The progression of the disease leads to more dependency
in daily life and finally death. The most common cause of
death is pneumonia, followed by suicide.
The motor symptoms and signs
The characteristic motor changes are involuntary,
unwanted movements. Initially, the movements often
occur in the distal extremities such as fingers and toes,
but also in small facial muscles. For bystanders these
muscle twitches are often invisible or can be explained
as nervousness. In daily life, walking becomes unstable
and the person can look as if he/she is slightly drunk.
Gradually the unwanted movements spread to all other
muscles from distal to more proximal and axial. Chorea-
tic movements are present all the time the patient is
awake. No single pattern exists, but facial choreatic
movements can lead to a continuous movement of facial
muscles where for instance an eyebrow is lifted, an eye
closed, the head is bent or turned while the tongue is
protruded with the lips pouting. The most prominent
are the extension movements of the long back muscles.
Talking and swallowing gradually become more proble-
matic leading to choking at any time in some patients.
In later stages the patient even becomes mute. Dysar-
thria and dysphagia become very prominent during the
course of the disease. All patients develop hypokinesia,
akinesia, and rigidity leading to a slower pace of all
activities (bradykinesia: slowness of movement) and a
severe hesitation in embarking on a movement (akinesia:
difficulty in starting movemevents)). The balance
between chorea and hypokinesia is determined individu-
ally. The extremes are on the one hand the younger
patient with an overwhelming rigidity (Westphal variant)
and on the other hand the very old patient severely
affected in the last stage of the disease with a long dura-
tion of illness, bed-bound with rigidity and flexion con-
tractures in the extremities. Dystonia is characterized by
slower movements with an increased muscle tone lead-
ing to abnormal posture, for instance torticollis, but also
rotation of the trunk or limbs. Dystonia (for instance
torticollis) can be the first motor sign in Huntington’s
disease. Other unwanted movements include tics, com-
parable to the ones seen in Tourette syndrome, but
these are fairly rare. Cerebellar signs can appear sporadi-
cally, similar to the presence of hypo- and hypermetria.
Walking is often described as ‘drunk’ or ‘cerebellar
ataxia’-like. Distinguishing between choreatic and ataxic
walking is very difficult. Pyramidal signs (Babinski sign)
are present incidentally.
The influence of motor disturbance on activities of
daily life progresses over time. The presence of hyperki-
nesia and hypokinesia results in difficulties in walking
and standing, and frequently leads to an ataxic gait and
frequent falls. Furthermore, daily activities such as get-
ting out of bed, taking a shower, dressing, toileting,
cleaning the house, cooking and eating become more
and more difficult. Depending on the kind of work the
patient does, motor signs will sooner or later interfere
with performance, even if psychiatric and cognitive
changes are still in the background.
Behaviour and psychiatric symptoms and signs
Psychiatric symptoms are very frequently present in the
early stage of the disease, often prior to the onset of
motor symptoms. The percentage of patients with psy-
chiatric signs varies between 33% and 76% depending on
the methodology of the study [4]. Because of their impact
on daily life, these symptoms and signs usually have a
highly negative impact on functioning and on the family
[5]. The most frequently occurring sign is depression.
The diagnosis is difficult because weight loss, apathy and
inactivity also occur in HD. Usually there is low self-
esteem, feelings of guilt and anxiety. Apathy is related to
disease stage, whereas anxiety and depression are not.
Suicide occurs more frequently in early symptomatic
individuals and also in premanifest gene carriers. Around
t h et i m eo ft h eg e n et e s ta n dt h es t a g ew h e ni n d e p e n -
dence diminishes are the most risky periods for suicide.
Anxiety also occurs frequently (34-61%), sometimes in
relation to uncertainty about the start and or the course
of the disease. Obsessions and compulsions can disturb
the patient’s life and also lead to irritability and aggres-
sion. Irritability is often the very first sign, in retrospect,
but in fact occurs during all stages of the disease [4]. The
way irritability is expressed varies enormously from ser-
ious disputes to physical aggression. A loss of interest
and increasing passive behaviour are seen as part of the
apathy syndrome. It can be difficult to discriminate
apathy from depression. Pychosis may appear, mainly in
the later stages of the disease. In most cases this goes
together with cognitive decline. The complete clinical
picture is comparable to schizophrenia with paranoid
and acoustic hallucinations. In the early stages, hyper-
sexuality can cause considerable problems in a relation-
ship. In the later stages hypo-sexuality is the rule.
Dementia
Cognitive decline is the other main sign of HD and can
be present long before the first motor symptoms appear,
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disease. The cognitive changes are particularly in rela-
tion to executive functions. In normal conditions, cogni-
tive and motor behaviour is goal-directed and planned.
Normally individuals are able to distinguish what is rele-
vant and what can be ignored, but patients with HD
lose this capability. The patients are no longer able to
organise their life or to plan things which in the past
were simple. They lose flexibility of mind, and can no
longer make mental adjustments. Misjudgements lead to
complicated situations, with patients no longer reacting
as they did in the past or in a way that the environment
expects. Language is relatively spared. Memory certainly
becomes impaired, although the semantic memory can
be spared to a certain extent. All psychomotor processes
become severely retarded [3].
Secondary symptoms and signs
From early on, an unintended weight loss has been
reported in all patients. As more attention is now paid to
this phenomenon, the loss seems to be a little less severe,
the cause being diverse. Although it seems logical to
think that chorea should play the main role in weight
loss, it has been shown that there is no relation between
weight loss and chorea or other movement disorders. A
relation with the length of the CAG repeat has been
described [6]. More practical issues, such as slower func-
tioning, decreased appetite, difficulty handling food and
swallowing certainly play a role. But hypothalamic neuro-
nal loss is also a causative factor [7,8].
Attention has only recently been focused on sleep-
and circadian rhythm disturbances of patients with HD
[9]. Autonomic disturbances can result in attacks of pro-
fuse sweating.
Juvenile Huntington’s disease
If the first symptoms and signs start before the age of 20
years, the disease is called Juvenile Huntington’sd i s e a s e
(JHD). Behaviour disturbances and learning difficulties
at school are often the first signs. Motor behaviour is
often hypokinetic and bradykinetic with dystonic com-
ponents. Chorea is seldom seen in the first decade and
only appears in the second decade. Epileptic fits are fre-
quently seen. The CAG repeat length is over 55 in most
cases. In 75% of the juveniles the father is the affected
parent [10].
Development of the disease
T h ec o u r s eo ft h el i f eo fap e r s o nw i t ho n ep a r e n tw i t h
Huntington’s disease can be divided into an at-risk, a
preclinical (A) and a clinical (B) stage. The at-risk stage
comes to an end when it is determined whether the per-
son carries the increased CAG repeat on chromosome 4.
If he does carry the gene, then he will go through the
preclinical and clinical stages until the end.
The clinical course is roughly divided into three parts
(Table 1), indicating a decrease in independence and
increase in the need for care. The clinical stage with
clear manifest signs is preceded by the premanifest gene
positive stage, and the transition or phenoconversion
phase, when more and more doubt about manifestations
of signs emerges. During periods of stress, irrespective
of whether this is physical or psychological, it is not
uncommon for clinical symptoms or signs to become
manifest. These signs can fade away temporarily when
the circumstances normalize. In the past, the first symp-
tom was always a motor sign. Dependent on the family’s
and the doctor’s experience with the disease, a diagnosis
was suggested. However, over the last 20 years it has
become clear [11,12] that psychiatric as well as cognitive
changes can be the first signs, many years before motor
signs become visible. If the non-motor signs are less
specific, it can be very difficult to make a diagnosis. In
retrospect, many patients mention a gradual change in
behaviour and performance at work. They stayed home
f o rs o m et i m ew i t ha‘burn-out’ or a ‘depression’.T h e s e
signs are rather non-specific and often have a plausible
explanation. With improved knowledge about the
genetic status and the course of the disease it has
become clear that these signs can be the first manifesta-
tion of Huntington’s disease.
Assessments
The clinical assessment of the symptoms and signs of
HD is important for patient, family and care-givers. To
follow the patient systematically, mainly for research
purposes, several scales have been developed. The best
known are the Shoulson and Fahn capability scale [13]
and the Unified Huntington Disease Rating Scale
(UHDRS) [14,15]. The UHDRS consists of a motor,
behaviour, cognitive and functional part, preceded by a
history and medication scheme. For the behaviour signs
an e ws c a l ew a sd e v e l o p e db yC r a u f u r d :t h eP r o b l e m
Behaviour Scale (PBS) [16]. Other scales, for instance
for the quality of life, are also in use. In the European
Network for Huntington disease (EHDN: website [17]) a
whole set of assessment scales has been devised, which
are now in use for over 6,000 patients in Europe.
Aetiology
Huntington’s disease is an autosomal dominantly inher-
ited disease caused by an elongated CAG repeat on the
short arm of chromosome 4p16.3 in the Huntingtine
gene [2]. This gene codes for the huntingtin protein and,
on exon 1, contains the CAG tract. The wild-type con-
tains a CAG repeat, coding for a polyglutamine stretch in
the protein at that site in the range 6 to 26. Huntington’s
disease is associated with 36 repeats or more. Definite
clinical manifestation will occur if the number of repeats
Roos Orphanet Journal of Rare Diseases 2010, 5:40
http://www.ojrd.com/content/5/1/40
Page 3 of 8exceeds 40. The range 36-39 leads to an incomplete
penetrance of the disease or to a very late onset. The
range between 29 and 35, the so-called intermediate
alleles, is unstable, which means that these alleles are
prone to changes during reproduction. Copying the gene
may lead to mistakes and very often leads to elongation
and seldom to shortening. This phenomenon is mainly
seen in the male line of reproduction [18].
An inverse correlation has been described between the
length of the repeat and the age at onset, determined by
the first motor manifestation. The longer the CAG
repeat, the earlier the onset. When the disease starts
before the age of 20 years, so-called juvenile Hunting-
ton’s disease (JHD), the repeat often exceeds 55 [5]. The
length of the repeat determines about 70% of the var-
iance in age at onset and gives no indication at all about
the initial symptom, the course, or the duration of ill-
ness. The only correlation now described is the faster
weight loss associated with a longer CAG repeat [6].
Anticipation phenomenon is seen in Huntington
families in the paternal line of inheritance.
The normal wild-type Huntingtin protein plays a role
in synaptic function, is necessary in the post-embryonic
period, possibly has an anti-apoptotic function and is
possibly protective against the toxic mutant, huntingtin
[19]. There is evidence that the mutant form leads to a
gain of function as well as to a loss of function. The
role of the mutation has been studied in many models:
cells, fibroblasts, C. Elegans, drosophila, mice, rat, sheep
and monkey. Mice models (more than 10 available) are
most commonly used. As neuronal intranuclear and
intracytoplasmic inclusions are found, it is still not clear
Table 1 Stages during the life of a Huntington’s disease patient
A. Preclinical stage
A1. At-risk stage (50%), one affected parent - Anxiousness for the future
- Uncertainty about carriership
- Care for affected parent
A2.Gene carrier, premanifest stage - Certainty about carriership
- New position in the family
- Renewed uncertainty about onset
- Care for affected parent and own family
A3. Transition phase - Strong feelings about changes in cognition
- Changes in behaviour
- Changes in motor activity
- Uncertainty remains
B. Clinical stage
B1. Clinical stage I - Presentation first symptoms: neurological, cognitive or psychiatric
- Chorea most prominent symptom
- Independent in ADL
- Burden for the family mainly psychological
- Rare death, unless suicide
B2 Clinical stage II - Motor disturbance more generalised
- Physical dependence starts
- Burden for family psychological and physical
- Death by other cause, suicide, euthanasia
B3. Clinical stage III - Severe generalised motor disturbance
- Almost complete physical dependence
- Patient completely dependent on care
- Burden for family mainly physical
- Death
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themselves or are they only a side-product of other
mechanisms? The inclusions are present in many areas
of the brain. The overall pathology, brain atrophy, parti-
cularly in the striatum with extensive neuronal loss, is
well known [20,21].
Diagnosis
The diagnosis is based on the clinical symptoms and
signs in a person with a parent with proven HD. First, it
is obligatory to take a precise history from the person
with symptoms followed by a detailed family history.
When all information has been obtained the diagnosis is
not very difficult, although non-specific clinical pictures
can be misleading. Also when the parent is not known
or has died due to another cause at a young age, the
clinical picture can be difficult to recognise. It is often
necessary to request old information in the form of
medical records and autopsy reports. The current gold
standard is DNA determination, showing a CAG-repeat
of at least 36 on the huntingtin gene on chromosome 4.
Before 1993, a family history with clinical and morpho-
logical verification in at least one of the parents or
grandparents was obligatory.
The clinical criteria currently necessary are still motor
changes with or without psychiatric or cognitive
changes. However, in most cases a combination of the
three main signs is present. The combination with the
family history is sufficient for diagnosis. No imaging,
general blood tests or other diagnostic tools are helpful.
For all diagnostic tests, it is necessary to obtain
informed consent from the patient. This is important
because if that person is given a diagnosis of Hunting-
ton’s disease, then probably many more individuals
around the patient will be confronted with an increased
risk of Huntington’s disease. Extensive studies are
underway to detect biomarkers (clinical, blood, MRI)
and hence the transition determining parameters [22].
Several studies are now focussing on changes in func-
tion and changes in brain imaging (MRI) before clinical
overt manifestation is present. It seems that brain
volume and brain connections show changes several
years before any clinical manifestation is present [23].
Differential Diagnosis
When chorea is the presenting and most prominent
sign, taking a history is the first and most valuable step.
The frequently occurring differential diagnoses for
m o t o rs i g nc h o r e aa r eg i v e ni nT a b l e2 .I nm a n yc a s e s
the underlying cause is another general internal disorder
or an iatrogenic disorder. Only very few genetically
determined disorders are responsible for choreatic syn-
dromes. In about 1% of the cases clinically diagnosed as
HD by the clinician, the genetic test does not confirm
the diagnosis. These are the so-called phenocopies [24].
Phenocopies are defined by a clinical diagnosis of HD
with chorea, psychiatric and or cognitive signs and an
autosomal dominant pattern of inheritance or family
history. In the last few years, several have been
described (Table 3)
Genetic Counselling
When the gene was localised on chromosome 4 in 1983
[25], premanifest diagnosis became available for the first
time using linkage analysis. Linkage analysis provided
the applicant with results, initially with a certainty of
93% and later with a certainty of about 98%. When in
1993 the CAG repeat on chromosome 4 was described,
real premanifest diagnosis could be given to those at
risk of HD. It was the first disease in which this techni-
que became practically available, functioning as an
example of how to cope with new questions and pro-
blems. A manifest was written by the HD community, a
collaboration of scientists, doctors and lay people [26].
The standard procedure was the following: step 1, con-
sultation with a clinical geneticist and preferably in
combination with a psychologist and a neurologist.
After 4-6 weeks a second consultation (step 2) takes
place including blood sampling. After a period of 6-
8 weeks a consultation (step 3) with disclosure is
planned. Exclusion criteria for the procedure are: age
Table 2 Differential Diagnosis for chorea
Hereditary - Huntington’s disease
- Benign hereditary chorea
- Neuroacanthocytosis
- DentatoRubroPallidoLuysianAtrophy (DRPLA)
- Wilson disease
Rheumatic disorders - Sydenham chorea
- Chorea gravidarum
Drug-induced - Neuroleptic drugs
- Oral anticonceptive drugs
- Phenytoine
- Levo-dopa
- Cocaine
Systemic disorders - Systemic Lupus Erythematodes (SLE)
- Thyrotoxicosis
- Polycythemia vera
- Hyperglycemia
- AIDS
- Paraneoplastic
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pressure for the applicant. Long discussions took place
concerning applicants with a 25% risk at the time of the
request. The procedure was extended with the rule that
maximal efforts must be taken by the applicant to get a
result from the parent with a 50% risk of HD. Finally
the 25% at risk applicant can get his test [27].
Prenatal diagnosis
As the test can be performed on any cell with a nucleus
containing DNA, antenatal diagnosis is also possible.
Between the 10
th and 12
th weeks of pregnancy, chorio-
nic villus sampling and between the 15
th and 17
th weeks
amniocentesis can be performed and DNA-testing car-
ried out. The procedure is only initiated if the parents
already know their own genetic status to prevent
unwanted disclosure for two individuals at the same
time. The procedure is embarked on with the intention
of ending the pregnancy if the HD gene is found in the
embryo. The mother cannot be forced to agree with this
conclusion.
If the parents have not yet been genotyped, one can
opt for an exclusion test by comparing the genetic status
of the embryo with that of the grandparents. In this
situation the result is either 0% risk for the foetus, and
so the parent keeps his or her 50% status, or 50% risk
for the foetus. The foetus has received a chromosome
from the affected grandparent, but it is not known to
which chromosome the HD gen is coupled. In this case
the foetus has a 50% risk, comparable to the parent, and
the parents can decide to abort a 50% at risk baby.
During the last decade, preimplantation diagnostics
has also been offered in several countries. The proce-
dure starts with in vitro fertilisation. When the embryo
is in its eight-cell stage, one cell is removed for DNA
testing. The embryo without the elongated CAG repeat
is placed in the mother’sw o m bt oa l l o wan o r m a lp r e g -
nancy to develop. Before starting this procedure, the
genetic status of the parent must be known, although
not all countries follow this line of thinking [28].
Management including treatment
Despite the fact that the pathogenesis of HD has still
not been resolved and a cure is not available, many
therapeutic options are available for treating symptoms
and signs with a view to improving quality of life.
Although many signs and symptoms can be treated, it is
not always necessary to do so. The patient’s limitations
in daily life determine whether or not drugs are
required. Very little evidence is available about the drug
or the dosage to prescribe for any signs and symptoms.
Drug treatment is, therefore, individualized and based
on expert opinion and daily practice.
Treatment consists of drug prescription and non-med-
ication advice. Surgical treatment does not play an
important role in HD and will be addressed only briefly.
Motor signs
Hyperkinesia, or chorea, is treated with dopamine recep-
tor blocking or depleting agents. Most commonly used
drugs for chorea (Table 4) are typical or atypical neuro-
leptics (dopamine receptor blocking) and tetrabenazine
(dopamine depleting). The drugs prescribed differ per
country. An extensive review of all medication is given
by Bonelli [29,30]. The most commonly used drugs for
depression and aggression are listed in Table 5. Cloza-
pine and olanzapine are atypical neuroleptics. Both have
an antichoreatic effect. Clozapine requires white cell
control in the blood and is, therefore, less practical,
making olanzapine the preferred drug. The most fre-
quently reported side effects are weight increase and
anti-depressive effects. From small case studies some
Table 3 Phenocopy of Huntington’s disease (OMIM) [32]
Mutation Locus
1. HDL1 octapeptiderepeatexpansion PRNP-gen 20pter.p12
2. HDL2 CTG/CAG-expansion JPH3-gen 16q24.3
3. HDL3 Not known 4p15.3
4. SCA17 (HDL4) CAG/CAA-expansion TBP-gen 6q27
5. SCA1/2/3 CAG-expansion ATXN1/2/3-gen 6p23, 12q24, 14q24-q31
6. DRPLA CAG-expansion ATN1-gen 12p13
7. Chorea-acanthocytosis mutation VPS13A-gen 9q
8. McLeod syndrome mutation XK-gen Xp21.2-21.1
9. NBIA2 mutation PLA2G6-gen 22q13.1
10. NBIA1/PKAN mutation PANK2-gen 20p13-12.3
11. Friedreich ataxia GAA-expansion FXN-gen 9q13; 9p23-p11
HDL = Huntington Disease-Like; SCA = Spinocerebellar ataxia; DRPLA = DentatoRubroPallidoLuysian Atrophy; NBIA = Neurodegeneration with Brain Iron
Accumulation; PKAN = Pantothenate-Kinase-Associated-Neurodegeneration.
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pine, ziprasidone, and risperidon. However, only tetrabe-
nazine, a dopamine depleting drug, has been shown in a
controlled trial to significantly reduce chorea [31]. The
most common side-effects are depression and sedation.
There is a long list of drugs without or with only a very
limited result, mostly in open case studies: a-tocopherol
amantadine, baclofen, cannabidiol, chlordiazepoxide,
choline, clonazepam, creatine, deanol, dextromethor-
phan, fluoxetine, idebenone, ketamine, lamotrigine, leva-
tiracetam, milacemide, minocycline, muscimol, OPC
14117, PUFA, remacemide, riluzole.
Drug treatment for hypokinesia has been tried using
antiparkinsonian drugs, but almost always with very dis-
appointing results. In practice, therefore, dopaminergic
drug are not prescribed.
To date, despite several claims, no drug is available
with any neuroprotective or disease-delaying effect. Dis-
ease modifying drugs are developed, but not available.
Also embryonic cell implants, still under study, are not
proven treatment options at the moment.
Surgical intervention to treat chorea has been
described in a few cases. Deep brain stimulation has a
place in other movement disorders such as Parkinson
disease.
In Alzheimer’s disease, anticholinesterase drugs are in
use. In Huntington’s disease no clinical trials with Rivas-
tigmine or Donepezil are available. In short-term, open
studies, no effect was found.
Psychiatric signs
As depression and aggressive behaviour are the most
d e v a s t a t i n gt of a m i l yl i f e ,t h em a j o r i t yo fd r u g sa r ep r e -
scribed for these signs. All advice is based on open stu-
dies and expert opinion. (Table 5)
Besides medication, many other care measures are
available. It is important to find the right therapy for
the right person at the right time. Non-medical inter-
ventions available are: physiotherapy, occupational
therapy, speech therapy, dietician, psychologist, social
worker, and nurse.
During the course of the disease, the patient requires
more care, which can also help his/her partner, for
e x a m p l eb yh a v i n gan u r s ea th o m et oh e l pw i t hs h o w -
ering. The burden for the caregiver can become too
heavy and so help must be found in day-care institu-
tions, usually connected to nursing home facilities. In
the period that follows the patient moves into a transi-
tion phase and eventually a 24-hour care situation.
Throughout the whole process of increasing depen-
dency, psychological help is often needed for the care-
giver, who has to deal with increasing responsibilities
while losing contact with his or her former partner.
Partner groups can be very useful. In general, lay organi-
zations play an enormous role in educating caregivers,
patients and families.
Medical and non-medical treatment must be individu-
ally tailored, as the symptoms and signs differ by person
and over time tremendously. Ideally treatment of
patients and their families should be organised by a
multidisciplinary team. Treatment is intended to
improve quality of life. To date, no cure is available
unfortunately.
Future perspectives
Huntington’s disease is a physically, psychologically and
socially devastating disorder. Knowledge about the dis-
ease and care for patients has increased enormously
over the last two decades. As the mean duration of ill-
ness is more than 17 years, one tends to forget the
many years prior to the onset of symptoms during the
at-risk and the preclinical periods, or the premanifest
period. Huntington’s disease is a lifelong disease for
both the individual and the family. From the moment
the gene was localised in 1983, and particularly after
1993, attention has focussed on the pathophysiological
pathway with the aim of developing a therapy. It was
the first autosomal dominant disease where premanifest
diagnosis became possible and it was the first trinucleo-
tide disease to be described. Consequently, since 1993
many researchers have developed an interest in this
Table 4 Drug treatment for chorea
Tiapride max 600 mg
Olanzapine max 20 mg
Tetrabenazine* max 200 mg
Pimozide max 6 mg
Risperidone max 16 mg
Fluphenazine max 10 mg
*When tetrabenazine is officially approved per country, this drug
will probably become the drug of first choice based on the
literature.
Hypokinesia None
(drug dosages vary individually; here maximal dosages are given; these are
seldom necessary in practice)
Table 5 Drug Treatment for depression (A) and
aggression (B)
A. Depression B. Aggression
Citalopram max 60 mg Citalopram max 60 mg
Fluoxetine max 60 mg Sertraline max 200 mg
Mirtazapine max 45 mgr Olanzapine max 20 mg
Valproinezuur max 2000 mg Dipiperon max 360 mg
Carbamazepine max 1600 mg Haloperidol max 10 mg
(drug dosages vary individually; here maximal dosages are given; these are
seldom necessary in practice)
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enormously.
What is the current perspective? The basic studies
mainly focus on the pathophysiology and the search for
biomarkers. A better understanding of the pathophysiol-
ogy will surely lead to drug development to interfere in
the pathological process. Drugs that can slow down,
delay, or stop the onset of the disease are being sought.
The second issue is the search for reliable, early to
detect and clinically relevant markers for onset of the
end course of the disease. In the search for biomarkers,
a very well organised study is underway: TRACK-HD, a
multinational study with 366 participants. This will end
in 2011 [22]. The Registry study, the main project of the
European Huntington Disease Network, also aims to
prepare the field for larger studies when drugs become
available for human testing.
In parallel with the rational pathway to find solutions
to treat this disorder, attention is being paid to finding
the best care for all patients and at-risk persons at this
point in time. The developments are promising, but one
thing is certain: the road to a solution is a long one.
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